

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Swan Joseph</u> <hr/> (Last) (First) (Middle) <u>105 / 8 CENTURY CIRCUIT</u> <hr/> (Street) <u>NORWEST,</u> <u>NEW</u> C3 <u>2153</u> <u>SOUTH</u> <u>WALES</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>11/28/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Incannex Healthcare Inc. [ IXHL ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Treasurer and Controller</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>1,000</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>11/28/2023</u>	<u>07/01/2025</u>	<u>Common Stock, par value \$0.0001</u>	<u>1,000</u>	<u>17.1</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>11/28/2023</u>	<u>07/01/2026</u>	<u>Common Stock, par value \$0.0001</u>	<u>1,000</u>	<u>20.39</u>	<u>D</u>	
<u>Stock Option (right to buy)<sup>(1)</sup></u>	<u>(1)</u>	<u>07/01/2027</u>	<u>Common Stock, par value \$0.0001</u>	<u>1,000</u>	<u>23.02</u>	<u>D</u>	

**Explanation of Responses:**

1. Granted on November 28, 2023. Vesting to occur on July 1, 2024, provided Mr. Swan is still employed on such date.

/s/ Joseph Swan

12/06/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.